Barton Ford Haynes, MD

Professor of Medicine
Frederic M. Hanes Distinguished Professor of Medicine
Director of the Human Vaccine Institute in the Department of Medicine
Professor of Immunology
Member of the Duke Cancer Institute
Member of the Duke Human Vaccine Institute
Campus mail 106 Research Drive, MSRBII 4090, Durham, NC 27710
Phone (919) 684-5384
Email address

The Haynes lab is studying host innate and adaptive immune responses to the human immunodeficiency virus (HIV), tuberculosis (TB), and influenza in order to find the enabling technology to make preventive vaccines against these three major infectious diseases.

Mucosal Immune Responses in Acute HIV Infection

The Haynes lab is working to determine why broadly neutralizing antibodies are rarely made in acute HIV infection (AHI), currently a major obstacle in the development of an HIV vaccine. The lab has developed a novel approach to define the B cell repertories in AHI in order to find neutralizing antibodies against the virus. This approach uses linear Immunoglobulin (Ig) heavy and light chain gene expression cassettes to express Ig V(H) and V(L) genes isolated from sorted single B cells as IgG1 antibody without a cloning step. This strategy was used to characterize the Ig repertoire of plasma cells/plasmablasts in AHI and to produce recombinant influenza mAbs from sorted single human plasmablasts after influenza vaccination.

The lab is also studying the earliest effect HIV-1 has on B cells. Analyzing blood and gut-associated lymphoid tissues (GALT) during acute HIV infection, they have found that as early as 17 days after transmission HIV-1 induces B cell class switching and 47 days after transmission, HIV-1 causes considerable damage to GALT germinal centers. They found that in AHI, GALT memory B cells induce polyclonal B cell activation due to the presence of HIV-1-specific, influenza-specific, and autoreactive antibodies. The team concluded from this study that early induction of polyclonal B cell differentiation, along with follicular damage and germinal center loss, may explain why HIV-1 induced antibody responses decline rapidly during acute HIV infection and why plasma antibody responses are delayed.

The lab is also looking at ways of generating long-lived memory B cell responses to HIV infection, another major hurdle in the development of a successful HIV-1 vaccine. The lab has found that in HIV-1 gp120 envelope vaccination and chronic HIV-1 infection, HIV-1 envelope induces predominantly short-lived memory B cell-dependent plasma antibodies.

Immunogen Design

To overcome the high level of genetic diversity in HIV-1 envelope genes, the Haynes lab is developing strategies to induce antibodies that cross-react with multiple strains of HIV. The lab has designed immunogens based on transmitted founder Envs and mosaic consensus Envs in collaboration with Dr. Bette Korber at Los Alamos National Laboratory. These immunogens are designed to induce antibodies that cross-react with a multiple subtype Env glycoproteins. The goal is to determine if cross-reactive mAbs to highly conserved epitopes in HIV-1 envelope glycoproteins can be induced. The team recently characterized a panel of ten mAbs that reacted with varying breadth to subtypes A, B, C, D, F, G, CRF01_AE, and a highly divergent SIVcpzUS Env protein. Two of the mAbs cross-reacted with all tested Env proteins, including SIVcpzUS Env and bound Env proteins with high affinity.

Mucosal Immune Responses in TB and Influenza

The Haynes lab is helping to develop novel approaches to TB vaccine development. The current therapeutic vaccine for TB, called BCG, may prevent complications from TB in children, but offers little protection against infection and disease in adults. The lab is focused on using live attenuated Mycobacterium tuberculosis mutants as vaccine candidates and is currently evaluating this approach in non-human primate studies. As part of the DHVI Influenza program, they are studying the B cell response to influenza in order to generate a “universal” flu vaccine. They are currently trying to express more highly conserved influenza antigens in recombinant vesicular stomatitis virus (rVSV) vectors in order to elicit robust T cell and antibody responses to those antigens.

Education and Training

  • M.D., Baylor University, 1973


Eeden, Charmaine van, Constantinos Kurt Wibmer, Cathrine Scheepers, Simone I. Richardson, Molati Nonyane, Bronwen Lambson, Nonhlanhla N. Mkhize, et al. “V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity.” Cell Rep 25, no. 11 (December 11, 2018): 3123-3135.e6.

Full Text

LaBranche, Celia C., Andrew T. McGuire, Matthew D. Gray, Shay Behrens, Peter D. Kwong, Xuejun Chen, Tongqing Zhou, et al. “HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.” Plos Pathog 14, no. 11 (November 2018): e1007431.

Full Text

Wagh, Kshitij, Edward F. Kreider, Yingying Li, Hannah J. Barbian, Gerald H. Learn, Elena Giorgi, Peter T. Hraber, et al. “Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth.” Cell Rep 25, no. 4 (October 23, 2018): 893-908.e7.

Full Text

Bradley, Todd, Dimitra Peppa, Isabela Pedroza-Pacheco, Dapeng Li, Derek W. Cain, Ricardo Henao, Vaishnavi Venkat, et al. “RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses.” Cell 175, no. 2 (October 4, 2018): 387-399.e17.

Full Text

Bradley, Todd, Guido Ferrari, Barton F. Haynes, David M. Margolis, and Edward P. Browne. “Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency.” Cell Rep 25, no. 1 (October 2, 2018): 107-117.e3.

Full Text

Bonsignori, Mattia, Eric Scott, Kevin Wiehe, David Easterhoff, S Munir Alam, Kwan-Ki Hwang, David C. Montefiori, et al. “Dual Maturation Pathways from the Unmutated Common Ancestor of HIV-1 Envelope Broadly Neutralizing Antibodies Overcome Glycan Barriers.” In Aids Research and Human Retroviruses, 34:111–111. MARY ANN LIEBERT, INC, 2018.


Williams, Wilton Bryan, R Ryan Meyerhoff, Hui Li, Priyamvada Acharya, Guillaume B. E. Stewart-Jones, Kevin Wiehe, Thomas B. Kepler, et al. “Macaque SHIV Induction of 2G12-like Broadly Neutralizing Antibodies.” In Aids Research and Human Retroviruses, 34:38–38. MARY ANN LIEBERT, INC, 2018.


Andrabi, Raiees, Chuancang Jiang, Jinsong Zhang, Amanda Newman, Ge Song, Jesper Pallesen, Gavin Gegg, et al. “Vaccine Induction of V2 Apex-directed, Cross-reactive Neutralizing Antibodies in CH01 UCA "HC Only" Knock-in Mice.” In Aids Research and Human Retroviruses, 34:121–121. MARY ANN LIEBERT, INC, 2018.


Wiehe, Kevin, Kevin O. Saunders, Todd Bradley, Willam J. Faison, Connor Hart, Cindy Bowman, Ashley Trama, et al. “Targeted Selection of an Improbable HIV-1 Antibody Mutation Critical for Broadly Neutralizing Reactivity With a Designed Immunogen.” In Aids Research and Human Retroviruses, 34:58–58. MARY ANN LIEBERT, INC, 2018.


Li, Hui, Ryan Roark, Shuyi Wang, Fang-Hua Lee, Wenge Ding, Alex Murphy, Juliette Rando, et al. “New SHIV Models of bNAb Elicitation and Env-Ab Coevolution.” In Aids Research and Human Retroviruses, 34:21–21. MARY ANN LIEBERT, INC, 2018.